Balyasny Asset Management
LENZ

Balyasny Asset Management’s LENZ Therapeutics LENZ Stock Holding History

Balyasny Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,747
Closed -$591K – 2502
2021
Q2 		$591K Buy
+2,747
New +$478K ﹤0.01% 1494

Other funds holding LENZ

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Balyasny Asset Management's LENZ Position: Q3 2021 in Review

Balyasny Asset Management sold out of LENZ Therapeutics (LENZ) in Q3 2021, closing a stake of 2,747 shares — an estimated $591K sold.

Balyasny Asset Management first reported a position in LENZ in Q2 2021 and held it in 1 quarter. The position peaked at $591K in Q2 2021. 60 funds tracked by Wall St. Rank hold LENZ as of Q3 2021.

  • Balyasny Asset Management reported no remaining LENZ Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Balyasny Asset Management sold 2,747 LENZ Therapeutics shares in Q3 2021, an estimated $591K.
  • Balyasny Asset Management first reported a position in LENZ Therapeutics in Q2 2021 and held it in 1 quarter.
  • Balyasny Asset Management's LENZ Therapeutics position peaked at $591K in Q2 2021.
  • 60 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2021.

Based on Balyasny Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.